van Mens LJJ, et al. - In this investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial, authors estimated the outcomes of the combination of golimumab plus methotrexate (MTX) as a first-line treatment vs MTX alone in inducing remission in psoriatic arthritis (PsA). They noted that the primary effectiveness endpoint was achieved by 81% of cases in the TNFi arm vs 42% in the MTX arm. They also observed a significant difference favorable to golimumab+MTX arm at week 22 for other response criteria like MDA, ACR20/50/70, disease measures and patient-reported outcomes. Similar occurrence rates of adverse event and treatment-emergent adverse event were reported in both arms.